Blog - Latest News
Published on

Why Relypsa Is Likely A Zero: The Chronic Hyperkalemia Treatment Market Is Small

Hyperkalemia, or high potassium in the blood, is unnecessary to treat unless it’s at a severe level.

Most medicare and most insurance companies don’t cover Veltassa for a reason.

Veltassa is inferior to its competitor, ZS-9, because ZS-9 can treat both acute and chronic hyperkalemia patients, while Veltassa can only treat the chronic market.

Veltassa’s black box label is a big drawback.There are problems with the drug and its trials, as revealed by government-funded researchers.

A potential Veltassa black swan event, And Relypsa’s CEO, John Orwin’s previous company’s deadly drug.

Read the full report on Seeking Alpha here.